3SBio Inc. Announces Expansion of its Leadership Team
SHENYANG, China, March 4, 2016 /PRNewswire/ -- 3SBio Inc. (Hong Kong: 1530) ("3SBio" and together with its subsidiaries the "3SBio Group") is pleased to announce thatKevin Xiao Weihong has joined 3SBio as its new chief operating officer. "We are pleased to welcome Kevin to 3SBio where he will p...
3SBio Signs Exclusive Patent License Agreement for ALT-P7, an Antibody-drug Conjugate Targeting HER2 with Alteogen
SHENYANG, China, and DAEJEON, Korea, Oct. 12, 2015 /PRNewswire/ -- 3SBio Inc. ("3SBio") (01530.HK), a leadingChina-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive licensing dea...
3SBio Inc. Selected as a Constituent of the Hang Seng Composite LargeCap & MidCap Index
SHENYANG, China, Aug. 17, 2015 /PRNewswire/ -- 3SBio Inc., (HKEX: 1530) ("3SBio") today announced that effectiveSeptember 14, 2015, it will be added as a constituent of the Hang Seng LargeCap & MidCap Index according to a press release issued by Hang Seng Indexes Company Limited ("Hang Seng") o...
3SBio Acquires Zhejiang Wansheng Pharmaceutical
SHENYANG, China, July 24, 2015 /PRNewswire/ -- - Adds integrated small molecule drug R&D and manufacturing platform - Expands product offering for chronic kidney disease and oncology patients - Further addresses unmet medical needs in diabetes-related complications and dermatology - Increas...
3SBio Acquires Global Rights to Anti-TNF mAb
SHENYANG, China, June 22, 2015 /PRNewswire/ -- 3SBio Inc., (HKEX: 1530) ("3SBio"), a leadingChina-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the ex-China global rights to Apexigen's ...
